|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2008-11-28
|
|
pubmed:abstractText |
Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice. Indirect evidence from clinical trials demonstrates that chronic inhibition of the renin-angiotensin-system (RAS) significantly reduces the incidence of AF. Since mechanisms of this protective effect of RAS-blockade are poorly understood, we directly tested proarrhythmic effects of angiotensin II (Ang II) in human atrial myocardium.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1388-9842
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1172-6
|
|
pubmed:dateRevised |
2011-6-8
|
|
pubmed:meshHeading |
pubmed-meshheading:18993115-Angiotensin II,
pubmed-meshheading:18993115-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:18993115-Atrial Fibrillation,
pubmed-meshheading:18993115-Cardiotonic Agents,
pubmed-meshheading:18993115-Female,
pubmed-meshheading:18993115-Heart,
pubmed-meshheading:18993115-Heart Atria,
pubmed-meshheading:18993115-Humans,
pubmed-meshheading:18993115-Incidence,
pubmed-meshheading:18993115-Isometric Contraction,
pubmed-meshheading:18993115-Male,
pubmed-meshheading:18993115-Muscle, Skeletal,
pubmed-meshheading:18993115-Myocardium,
pubmed-meshheading:18993115-Renin-Angiotensin System,
pubmed-meshheading:18993115-Risk Factors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Direct pro-arrhythmogenic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium.
|
|
pubmed:affiliation |
Department of Cardiology, Medical University Graz, Graz, Austria. dirk.von-lewinski@meduni-graz.at
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
